We further highlight very recent advances in our understanding how metabolic sources and pathways can impact on the balance between IFN‐γ+ and IL‐17+ γδ T cells in the tumor microenvironment, which opens a new exciting avenue to explore toward the application of γδ T cells in cancer immunotherapy. The gene discussed is IL17A; the disease is neoplasm.